Abstract

Treatment with I.C.R.F. 159 completely inhibited metastasis formation in mice implanted with Lewis lung carcinoma at doses having little influence on the rate of growth of the primary implant. This inhibition was due to the effect of I.C.R.F. 159 on the development of blood vessels of the invading margins of the primary tumour. So far as is known, this is the first time a drug has induced a specific loss of the malignant characteristic of blood-borne tumour cell dissemination.

Keywords

Lewis lung carcinomaMetastasisCancer researchLungGrowth inhibitionCarcinomaPrimary tumorMedicineChemistryCell growthPathologyBiologyInternal medicineCancerBiochemistry

Related Publications

Fibroblasts in cancer

Tumours are known as wounds that do not heal - this implies that cells that are involved in angiogenesis and the response to injury, such as endothelial cells and fibroblasts, h...

2006 Nature reviews. Cancer 4355 citations

Publication Info

Year
1970
Type
article
Volume
4
Issue
5731
Pages
344-346
Citations
90
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

90
OpenAlex

Cite This

A. J. Salsbury, Karen Burrage, K. Hellmann (1970). Inhibition of Metastatic Spread by I.C.R.F. 159: Selective Deletion of a Malignant Characteristic. BMJ , 4 (5731) , 344-346. https://doi.org/10.1136/bmj.4.5731.344

Identifiers

DOI
10.1136/bmj.4.5731.344